Three-function dual-specific antibody Catumaxomab treats peritoneal cancer and is licensed by NMPA to begin phase 3 clinical trials worldwide.

Lintonpharm, !----, announced that the State Drug Administration of China (NMPA) has authorized the company's bispecific antibody Catumaxmab to treat patients with peritoneal cancer in Phase III clinical trials (NCT04222114)peritoneal cancer is a type of advanced stomach cancer that has spread to the abdominal cavityCatumaxomab is the first T-cell binding bispecific antibody approved by the European Medicines Agency (EMA) in 2009 to treat malignant ascitesmalignant ascites are cessal fluid, indicating the presence of malignant cells"Gastric cancer is the sixth most common cancer in the world," said DrHorst Lindhofer, co-founder and chief scientific officer ofLinton Pharm70% of patients are in China, and most are diagnosed with advanced conditionsGiven this high unmet demand, we hope catumaxomab will provide new treatment options" about advanced gastric cancer with peritoneal cancer (PC) is one of the main causes of death of advanced stomach cancer, PC gastric cancer has a very poor prognosis, the expected survival of less than a yearCurrent treatments forstomach cancer include her2-positive patients using qural monites and systemic chemotherapylimited options for patients with first-line treatment failuresabout Catumaxb Catumaxomab is a three-function bispecific antibody that binds to the transmembrane glycoprotein-epithelial cell adhesion molecule (EpCAM) and CD3 on the T-cell on the tumor cell, and also collects immune-assisted cells through fc-sireR bindingCatumaxomab kills tumor cells through T-cells and auxiliary cell-mediated cytotoxicity, and has long-term vaccine potential for tumor cells due to its unique Fc-R binding and activation propertiesPicture Source: